Anticoagulant-related nephropathy: systematic review and meta-analysis

Karolinny Borinelli de Aquino Moura¹, Paula Marques Prates Behrens¹, Rafaela Pirolli¹, Aimee Sauer¹, Dayana Melamed¹, Francisco Veríssimo Veronese² and André Luis Ferreira Azeredo da Silva¹

¹Division of Internal Medicine, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil and ²Division of Nephrology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil

ABSTRACT

Background. The aim of this study was to report the prevalence and mortality associated with anticoagulant-related nephropathy (ARN) through a systematic review of the literature.

Methods. Electronic searches were conducted in the Medline and EMBASE databases, and manual searches were performed in the reference lists of the identified studies. The studies were selected by two independent researchers, first by evaluating the titles and abstracts and then by reading the complete texts of the identified studies. Case series, cross-sectional studies, cohort studies and case–control studies reporting the prevalence and factors associated with ARN were selected. The methodological quality was assessed using the Newcastle–Ottawa scale. Meta-analyses of the prevalence of ARN and 5-year mortality using the random effects model were performed when possible. Heterogeneity was assessed using the $I^2$ statistic.

Results. Five studies were included. Prevalence of ARN ranged from 19% to 63% among the four included cohort studies. Meta-analysis of these resulted in high heterogeneity ($I^2$ 96%, summary effect 31%; 95% confidence interval (CI) 22–42%). Subgroup meta-analysis yielded an ARN prevalence of 20% among studies that included patients with fewer comorbidities ($I^2$ 12%; 95% CI 19–22%). In a direct comparison, meta-analysis of the 5-year mortality rate between anticoagulated patients who had experienced ARN and anticoagulated patients without ARN, patients with ARN were 91% more likely to die (risk ratio $= 1.91$; 95% CI 1.22–3; $I^2$ 87%). Risk factors for ARN that were reported in the literature included initial excessive anticoagulation, chronic kidney disease, age, diabetes, hypertension, cardiovascular disease and heart failure.

Conclusions. ARN studies are scarce and heterogeneous, and present significant methodological limitations. The high prevalence of ARN reported herein suggests that this entity is underdiagnosed in clinical practice. Mortality in patients with ARN seems to be high compared with patients without this condition in observational studies.

Keywords: anticoagulant-related nephropathy, meta-analysis, systematic review, warfarin, warfarin-related nephropathy
INTRODUCTION

Oral anticoagulation is widely used for preventing and treating clinical conditions related to thromboembolic phenomena. Although novel oral anticoagulants (NOacs), such as direct thrombin inhibitors and factor Xa inhibitors, do not require regular monitoring of anticoagulation, warfarin remains the most prescribed agent.

Anticoagulant-related nephropathy (ARN) is a complication associated with the use of anticoagulants that has been reported in recent years, especially in cases involving warfarin-related nephropathy (WRN). This condition is frequently underdiagnosed and is characterized by the following criteria, which may not occur together: (i) excessive anticoagulation [international normalized ratio (INR) >3 in most studies]; (ii) haematuria; and (iii) acute renal failure (ARF) unexplained by other causes (worsening of baseline creatinine by >0.3 mg/dL). In a case series of patients with ARN, Brodsky et al. [1] identified characteristic features of ARN in renal biopsies, including acute kidney injury, presence of red blood cells in Bowman’s space and renal tubular obstruction by red blood cell casts. Moreover, the reported rate of ARN is higher in patients affected by chronic kidney disease (CKD) [2], which might be a risk factor for ARN.

This systematic review of ARN in humans was conducted to better characterize the epidemiological aspects, risk factors and associated renal outcomes.

MATERIALS AND METHODS

Selection of studies and data extraction

The EMBASE and Medline databases were searched for articles on ARN. The searches were conducted with no start date specified and an end date of November 2017, without language restrictions. These records were screened based on the title and abstract, and the full text of the selected records were subsequently evaluated independently by two researchers. Disagreements were resolved by consensus or by arbitration of a third reviewer, either a methodologist or a nephrologist, depending on the nature of the disagreement. Data were extracted by two researchers independently. The complete search strategy is presented in Supplementary data, Appendix S1. The protocol of this systematic review was recorded in PROSPERO (CRD42017081431).

Inclusion criteria

Observational studies and case series with five or more participants with data on the rate of ARN and clinical characteristics of patients undergoing anticoagulant therapy by any indication were included. Case reports or case series with four or fewer participants, in vitro studies or animal studies were excluded.

Outcomes

The primary outcome to be analysed was the prevalence of ARN. The secondary outcomes evaluated included mortality, progression to end-stage kidney disease, and clinical and socio-demographic characteristics related to the development of ARN.

Risk of bias

Two researchers assessed the risk of bias in each study independently using the Newcastle–Ottawa scale for cohort studies [3], in which a maximum score of 9 was possible, and 7 was the threshold for high quality.

Statistical analysis

Single-arm meta-analysis was performed to obtain a summary measure of the observed frequency of ARN in the identified studies. In a direct comparison risk ratio (RR), meta-analysis comparing mortality rates between patients with and without ARN was performed. Heterogeneity was assessed by the I² statistic, with cut points of 25 and 75% for low, intermediate and high heterogeneity. Moderate to high heterogeneity was explored by subgroup analysis whenever possible. For all meta-analyses, summary frequencies and their 95% confidence intervals (CI) were calculated using the random effects model, and the results are represented in forest plots. The analyses were conducted using the softwares comprehensive meta-analysis version 2 (Biostat, Englewood, NJ, USA) and R revision 3.5.0 (package Meta). Outcomes that were not subjected to meta-analysis because of insufficient data or non-reconcilable differences in the way they were reported between the studies were presented in tabular form.

RESULTS

Selection of studies

Electronic searches identified 53 unique records. In the end, five studies met the inclusion criteria of this systematic review. The anticoagulant drug evaluated in all five studies was warfarin, and none of the evaluated studies reported NOAC-related nephropathy. The study selection flowchart is shown in Figure 1. The reasons for not including studies in the full-text evaluation phase are presented in Supplementary data, Appendix S2.

Characteristics of the studies and participants

The analysed studies were predominantly historical cohorts, except for the study by Brodsky et al. [1], which is a case series. Most of the studies used supratherapeutic INR (>3) associated with creatinine measurements in distinct time points as an inclusion criterion. Two studies used inclusion criteria that were distinct from those of the other studies, and patients at higher risk of anticoagulation complications were included. The study by Lim and Campbell [4] included patients with any INR, and the sample consisted of anticoagulated patients admitted to a general care unit for any cause. The study by Brodsky et al. [2] published in Nephron Clinical Practice also included a sample composed exclusively of chronic renal patients. All included studies excluded patients with end-stage renal disease undergoing renal replacement therapy (RRT).

In the included studies, ARN was usually characterized by the appearance of ARF according to the Acute Kidney Injury Network (AKIN) [5] criteria (worsening of baseline creatinine by 0.3 mg/dL compared with baseline levels) related to a hypercoagulability state (INR >3). The follow-up period ranged from 23 months to 5 years. The characteristics of the included studies are summarized in Table 1.

The indication of anticoagulation for the majority of patients studied in different cohorts was atrial fibrillation (AF). Deep venous thrombosis or pulmonary thromboembolism were the second most frequent causes. Other indications were valve replacement, stroke and anti-phospholipid antibody syndrome.

The frequency of ARN, defined by criteria of the AKIN guideline, ranged from 19.3% to 63.0% in the five identified cohort studies. All
nine cases reported by Brodsky et al. [1] had the diagnosis of ARN confirmed by biopsy. ARN was more common in patients with pre-existing CKD [6–8]. The frequencies of comorbidities and of concomitant use of other drugs are described in Table 2, and the main results of the included studies are shown in Table 3.

**Possible risk and protective factors**

Possible risk factors for ARN were reported in all studies. Lim and Campbell [4] reported that after multivariate analysis, the risk factors were heart failure (odds ratio (OR) = 1.64, 95% CI 1.19–2.25; P = 0.002) and alanine aspartate aminotransferase (AST) at the time of INR > 3 with interquartile intervals between 38 and 7002 (OR = 2.29, 95% CI 1.51–3.46; P < 0.001). Brodsky et al. [8] found that the risk factors were age (63.7 ± 14.7 years in patients with ARN and 61.7 ± 15.6 years in patients without ARN; P = 0.025), diabetes (47% in patients with ARN and 37% in patients without ARN; P < 0.001), hypertension (82% in patients with ARN and 72% in patients without ARN; P < 0.001) and heart failure (62% in patients with ARN and 52% in patients without ARN; P < 0.001). These authors identified similar risk factors in a subsequent study. In a third study, Brodsky et al. [2] found that excessive anticoagulation in the first 3 months of warfarin use appeared to be a risk factor for ARN (33.3% in patients with ARN and 12.9% in patients without ARN; P = 0.087). Lim and Campbell [4] used the risk, injury, failure, loss of renal function, end-stage renal disease classification (RIFLE) criteria [9] and identified the following risk factors for ARN: haematuria (RR = 1.90, 95% CI 1.19–3.01; P = 0.01), urinary infection (RR = 1.68, 95% CI 1.05–2.7; P = 0.03), hypotension (RR = 2.42, 95% CI 1.55–3.78; P = 0.001) and hypovolaemia (RR = 6.04, 95% CI 2.51–14.6; P < 0.001). In this same study, the rapid normalization of the INR with plasma, prothrombinex or vitamin K, but not excessive anticoagulation per se, was associated with an increased risk of ARN (RR = 1.8, 95% CI 1.10–2.92; P = 0.03). For CKD, the only identified risk factor was heart failure on admission (RR = 8.2, 95% CI 1.78–38.1; P = 0.002).

There was no correlation between the magnitude of the increase in INR and the risk of ARN in most cases. There were exceptions in the studies by Brodsky et al. [7, 8] and An et al. [6], which reported that INR tended to be higher in patients with ARN.

With regard to possible protective factors for ARN, An et al. [6] identified AF (OR = 0.56, 95% CI 0.4–0.8; P < 0.001) and serum albumin of 3.2–5.3 g/dL. Furthermore, the higher was the albumin level, the lower was the risk of ARN (albumin of 3.2–3.6 g/dL: OR = 0.46, 95% CI 0.31–0.67; P < 0.001; albumin of 3.7–4.0 g/dL: OR = 0.27, 95% CI 0.18–0.27; P < 0.001; and albumin of 4.1–5.3 g/dL: OR = 0.19, 95% CI 0.12–0.30; P < 0.001).

**Meta-analyses**

Cohort studies with sufficient information were included in the meta-analyses of the outcomes ARN prevalence and mortality among ARN patients. The case series of Brodsky et al. [1] was not included in the meta-analyses.

The prevalence of ARN was estimated at 31% (95% CI 22.0–42.0), with a heterogeneity (I²) of 96%. The meta-analysis of ARN prevalence is presented in Figure 2. With respect to the causes of the high heterogeneity in the meta-analysis, the inclusion criteria in the studies by Brodsky et al. [2] and Lim and Campbell [4] were distinct from those used in the other studies, resulting in the recruitment of patients with more comorbidities. Meta-
Table 1. Characteristics of the studies included in the systematic review and meta-analyses

| Study, year | Study design | Inclusion criteria | Exclusion criteria | GFR method | Definition of CKD/ARF | Definition of ARN | Follow-up | Rating using the Newcastle-Ottawa scale |
|-------------|--------------|--------------------|-------------------|-------------|----------------------|-------------------|-----------|-----------------------------------------|
| An et al. [6] | Historical cohort | >18 years, INR >3 with creatinine measured 1 week after the event and 6 months before | RRT; baseline GFR > 175 mL/min | MDRD | CKD; GFR <60 mL/min | Creatinine increase >50% or >0.3 1 week after INR >3 | 23.3 ± 26.8 months | 7 |
| Brodsky et al. [8] | Historical cohort | NA | NA | NA | Increase in creatinine by >0.3 mg/dL 1 week after INR >3 | 5 years | 6 |
| Brodsky et al. [7] | Historical cohort | INR >3 (serum creatinine measured 1 week after and 3 months before the episode) | Prisoners, <18 years, end-stage renal failure, significant bleeding 1 week after INR >3 | CKD-EPI | ARF: Increase in creatinine ≥0.3 mg/dlCKD: ICD-9 585.1–585.5 or 585.9 | Increase in creatinine ≥0.3 mg/dl within 1 week of INR >3 | 5 years | 8 |
| Lim and Campbell [4] | Prospective cohort | Elderly who remained in a general care unit for ≥1 day | Readmission <28 days, INR <2, terminal stage, IUC, UTI, dialysis | MDRD and Australasian Creatinine Consensus Working Group | ARF: RIFLE or AKIN | NA | 4–6 weeks | 9 |
| Brodsky et al. [2] | Historical cohort | CKD (Stage 2–4), episode of INR >3, creatinine measurements 1 year before, after and within 1 week after episode, and medical record | Another medical condition at the time of INR >3 that explained the ARF | NA | ARF: Increase in creatinine ≥0.3 mg/dL | Increase in creatinine ≥0.3 mg/dl in during INR >3 | 2 years | 6 |
| Brodsky et al. [1] | Case series | Renal biopsy unexplained ARF and haematuria | Active/acute glomerulonephritis | GFR in mL/min | NA | Compatible biopsy | 5 years | NA |

GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; eGFR (mL/min/1.73 m²) = 175 × (SCr)⁻¹.⁵⁴ × (age)⁻⁰.⁷⁰³ × 0.۷۴۲ [if female] × ۱.۲۱۲ [if Black]. NA, not available; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; IUC, indwelling urinary catheter; UTI, urinary tract infection; AKIN, Acute Kidney Injury Network.
Table 2. Characteristics of patients included in the systematic review and meta-analyses

| Study            | N     | Male (%) | Age (years), mean ± SD | AF  | Stroke | Deep venous thrombosis | PTE | Prevalence of CKD (%) | Diabetes | Hypertension | Heart failure | Comorbidities (%) |
|------------------|-------|----------|------------------------|-----|--------|------------------------|-----|-----------------------|----------|--------------|---------------|-------------------|
| An et al. [6]    | 1297  | 51.7     | 68.4 ± 12.5            | 40.7| 44.8   | 13.4                   | 12  | 28.3                  | 37       | 80.8         | 32.8          | NA                |
| Brodsky et al. [8]| 4059  | NA       | 63.7 ± 14.7b           | NA  | NA     | NA                     | NA  | NA                    | 12.5     | 40.7          | 44.8          | NA                |
| Brodsky et al. [7]| 4006  | 52.82    | 63.6 ± 14.7b           | NA  | NA     | NA                     | NA  | 22.7                  | 39.1     | 74            | 46             | NA                |
| Lim and Campbell [4]| 150   | 62       | 80 ± 8.0               | 82  | NA     | NA                     | 7.3 | 90.66                 | 24       | 60.7          | 48             | 39.1              |
| Brodsky et al. [2]| 49    | 55.1     | 59.08 ± 16.1b          | 53.0| NA     | 30.6                   | NA  | 100                   | NA       | NA           | 36.7          | NA                |
| Brodsky et al. [1]| 9     | 55.5     | 61.6                   | NA  | NA     | NA                     | NA  | 100                   | NA       | NA           | NA            | 36.7              |

\*Angiotensin-converting enzyme inhibitors (44.7%), angiotensin 2 receptor blockers (24.7%), diuretics (59.3%) and \(\beta\)-blockers (9.3%).

\*bWith ARN.

\*cWithout ARN.

PTE, pulmonary thromboembolism; NSAIDs, non-steroidal anti-inflammatory drugs; NA, not available.

Table 3. Main results of studies included in the systematic review and meta-analyses

| Study            | Prevalence of ARN (%) | 5-year mortality (%) | Baseline creatinine (mg/dL) | Creatinine at the time of excessive anticoagulation (mg/dL) | Mean INR in anticoagulated patients |
|------------------|-----------------------|----------------------|-----------------------------|-----------------------------------------------------------|-----------------------------------|
|                  | General               | With ARN             | Without ARN                 | General                                                  | With ARN                      |
| An et al. [6]    | 19.3 (250/1297)       | 10.6                 | 8.59                        | 1.05 ± 0.86                                              | 1.13 ± 0.99                   | 1.03 ± 0.83                   | 1.16 ± 0.94 | 1.93 ± 1.44 | 0.98 ± 0.66 | 3.89 ± 1.24 | 4.19 ± 0.56 | 3.82 ± 1.14 |
| Brodsky et al. [7, 8]| 20.6 (838/4059)      | 30.1                 | 27.01                       | NA                                                       | NA                            | NA                           | NA                           | NA              | 4.8 ± 2.2 | NA         | NA         |
| Lim and Campbell [4]| 63 (51/81)         | NA                   | NA                          | 1.24 ± 0.48\*a                                          | NA                            | NA                           | NA                           | NA              | NA              | 4.91 ± 3.1 | 4.21 ± 1.3 |
| Brodsky et al. [2]| 36.7 (18/49)         | NA                   | NA                          | 1.42 ± 0.53                                              | NA                            | NA                           | NA                           | 4.3             | NA              | NA         |
| Brodsky et al. [1]| 40 (9/9)             | NA                   | NA                          | 1.2                                                      | NA                            | NA                           | NA                           | NA              | NA              | NA         |

\*To convert \(\mu\)mol/L to mg/dL, divide by 88.0.

\*bData are presented as mean ± SD.

ARN, Anticoagulant-related nephropathy; NA, not available; INR, international normalized ratio.
analysis of subgroup of studies (Figure 3) was performed as a sensitivity analysis and yielded a 20% prevalence of ARN with only 12% heterogeneity between the two studies with comparable inclusion criteria (An 2013 [6] and Brodsky 2010 [8]).

In a direct comparison, meta-analysis (Figure 4) of the risk of death in 5 years between anticoagulated patients exposed to ARN and anticoagulated patients not exposed to ARN, patients exposed to ARN were 91% more likely to die (RR = 1.91; 95% CI 1.22–3.0; I² 87%).

**DISCUSSION**

To the best of our knowledge, this is the first systematic review of ARN to date. Although our systematic review has focussed on anticoagulants in general, only studies on warfarin were identified. Thus our results do not apply to anticoagulant agents in general, and we have not found evidence to support or to exclude the association of other coumarin derivates (e.g., acenocumarol) or other newer anticoagulants to nephropathy.

Most available studies are case reports, which were not included in the present review. This review selected five cohort studies and one series of nine cases with histopathological analysis of ARN. In the present study, we decided to perform quantitative synthesis of information whenever possible due to the novelty and to the scarcity of information on the subject of ARN. One of the main reasons to perform meta-analysis is to pool results of available studies as a means of reaching a better understanding of clinical phenomena.

The prevalence of ARN in the identified studies varied significantly according to the risk of the study population and reached 63% in high-risk patients, including those requiring hospitalization [4]. However, the best estimate of prevalence in the present study was 20.4%, obtained by the meta-analysis of three representative studies of outpatients undergoing anticoagulation therapy with warfarin using sensitivity analysis that excluded studies on populations with high risk of ARN.

With respect to 5-year mortality, although there appears to be an increased risk of death among patients with ARN in the meta-analysis of this outcome’s frequency, the limited number of studies and the lack of direct comparisons between patients with and without ARN prevented us from making definitive conclusions.

It is believed that the pathophysiological mechanisms associated with ARN are multifactorial. Macroscopically, the lesions caused by ARN are formed by rupture of the glomerular filtration barrier with consequent haemorrhage of capillaries and Bowman’s space and obstruction of renal tubules by red blood cell casts, resulting in damage to the tubular epithelium [1, 10–12]. However, the mechanisms at the cellular and biochemical levels are poorly understood. There is direct damage...
to tubular epithelial cells by oxidative stress, in which free hae-
moglobin binds to receptors in tubular cells, dissociates into
globin and haem, and activates the formation of reactive
oxygen species, lipid peroxidation and pro-inflammatory path-
ways [13–15]. Warfarin may inhibit the activation of Gla matrix
protein and the growth arrest-specific gene 6, affecting glomerular
haemodynamics and the migration of smooth muscle cells,
leading to vascular calcification and apoptosis [16]. Animal
model studies suggest that anticoagulants cause direct glomer-
ular damage by inhibiting the activation of vitamin K-depen-
dent proteins such as thrombin, preventing the activation
of the proteinase-activated receptor, thereby destabilizing the
capillary endothelium and inducing glomerular haemorrhage
[11, 17].

The present systematic review identified candidate risk fac-
tors for ARN in the included studies, including age, diabetes, hy-
pertension, pre-existing CKD, cardiovascular disease and heart
failure [4, 7, 8]. In addition, there are factors related to warfarin
anticoagulation in other contexts, including excessive anticoa-
gulation at the onset of warfarin use [2, 6, 7], excessive anticoa-
gulation (INR >3) in the presence of hypoalbuminaemia and
increased AST after an increase in INR [6], anticoagulation in
patients with underlying glomerulopathies such as immuno-
globulin A nephropathy [18] and thin glomerular basement
membrane disease [19], and genetic polymorphisms such as a
variant of the CYP2C9*3 gene associated with increased risk of
bleeding [20]. Despite the rationale for a true association of
these possible risk factors with a higher frequency of ARN, the
available information is still limited, and there may be con-
 founding bias. All of the possible risk factors for ARN that were
reported in the included studies are themselves causes of acute
kidney injury, and there was insufficient adjusting for con-
founding. For instance, there was no adjusting for albuminuria
in the assessment of hypoalbuminaemia as a risk factor in the
study by An et al. [6]. Likewise, the report by Lim and Campbell
[4] that rapid normalization of INR was also a risk factor is in it-
sel l a confounding factor for a causal relationship. These and
other examples weaken the credibility of a potential cause-and-
effect relationship to warfarin. Thus, the identification of risk
factors for ARN remains an open question.

In practical terms, most experts recommend that, in cases of
suspicion of ARN, anticoagulants are discontinued (if possible)
or their dose is reduced and adjusted for therapeutic levels of
the INR. There is no evidence that reversal of an excessive anti-
coa gulation state limits renal injury. However, prolonged peri-
ds of supratherapeutic INR can maintain and aggravate
tubular damage and glomerular haemorrhage [11]. Other feasible
strategies for decreasing the risk of ARN include antiplatelet
therapy suspension and control of arterial hypertension [11].
With respect to the monitoring of renal function in anticoagu-
lated patients, the guidelines of the European Heart Rhythm
Association recommend quarterly monitoring [21]; however,
this interval may be too long to identify ARN because ARN may
occur within the first few weeks of drug use. The use of N-ace-
tethylcysteine [13] and corticosteroids [22] is restricted to an experi-
mental study or a case report, respectively, without clinical
evidence of their efficacy.

Some experts recommend the monthly monitoring of serum
creatinine in the first 3 months of anticoagulation therapy and
quarterly monitoring after this period [11]. In most patients
with ARN, serum creatinine levels are maintained or decreased
in the first few weeks after correction of coagulopathy [1]. In
cases in which serum creatinine continues to increase or
remains elevated above baseline after resolution of
cogulopathy, differential diagnosis with another condition
should be performed by renal biopsy. Biopsy should also be per-
formed in cases in which haematuria persists or develops after
achieving therapeutic INR, suggesting underlying glomerulone-
phritis [18] or structural changes in the glomerular basement
membrane, including thin glomerular basement membrane dis-
ease [19]. However, it is of note that renal function is not recov-
ered or is only partially recovered in some patients [7], and
patients with CKD are more susceptible in this context [2].

Some limitations of this systematic review should be
addressed: (i) the very high heterogeneity and the lack of suffi-
cient information to permit confounder-adjusted comparative
mortality risk meta-analyses precludes the use of the estimated
summary effects for practical applications; (ii) the impossibility
of performing a meta-analysis of the possible risk factors of
ARN; (iii) the impossibility of excluding the occurrence of publi-
cation bias because of the small number of studies included and
the limited understanding of the nature of this type of bias in
systematic reviews of observational studies; and (iv) despite
these limitations, we believe that we are providing a valuable
contribution to the literature by identifying and organizing,
through a systematic review and meta-analysis, a set of cur-
cently available studies on a recently described relevant clinical
entity.

In conclusion, WRN is a real clinical entity with clinical defi-
nition and histopathological documentation. The rate of WRN
was high in the clinical studies identified in the present system-
atic review, and this complication seems to be underdiagnosed
in care practice. There are no clinical–epidemiological studies
on NOAC-related nephropathy, and the presence of this associ-
ation is unknown.

SUPPLEMENTARY DATA

Supplementary data are available at ckJ online.

ACKNOWLEDGEMENTS

The authors are grateful to the Internal Medicine Service
and the Nephrology Service of the Hospital de Clínicas de
Porto Alegre for their support. Special thanks to Professor
Renato de Borba Mello for suggestions and comments on
the manuscript.

AUTHORS’ CONTRIBUTIONS

All authors contributed equally to the present work. All
authors have read and approved the manuscript as submit-
ted, are qualified for authorship and take full responsibility
for its content.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES
1. Brodsky SV, Satoskar A, Chen J et al. Acute kidney injury dur-
ing warfarin therapy associated with obstructive tubular red
blood cell casts: a report of 9 cases. Am J Kidney Dis 2009; 54:
1121–1126
2. Brodsky SV, Collins M, Park E. Warfarin therapy that results in
an international normalization ratio above the
therapeutic range is associated with accelerated progression of chronic kidney disease. *Nephron Clin Pract* 2010; 115: 142–146

3. Wells GA, Shea B, O’Connell D et al. *The Newcastle-Ottawa scale (NOS) for Assessing the Quality of Nonrandomised studies in Meta-analyses.* http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (25 April 2016, date last accessed)

4. Lim AK, Campbell DA. Haematuria and acute kidney injury in elderly patients admitted to hospital with supratherapeutic warfarin anticoagulation. *Int Urol Nephrol* 2013; 45: 561–570

5. Mehta RL, Kellum JA, Shah SV et al. *Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.* *Crit Care* 2007; 11: R31

6. An JN, Ahn SY, Yoon C-H et al. The occurrence of warfarin-related nephropathy and effects on renal and patient outcomes in Korean patients. *PloS One* 2013; 8: e57661

7. Brodsky SV, Nadasdy T, Rovin BH et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. *Kidney Int* 2011; 80: 181–189

8. Brodsky SV, Hebert L, Wu H et al. Increased INR >3.0 in patients on warfarin therapy is associated with acute changes in the serum creatinine and increased mortality rate. *Blood* 2010; 116: 819

9. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. *Kidney Int* 2008; 73: 538–546

10. Narasimha Krishna V, Warnock DG, Saxena N et al. Oral anticoagulants and risk of nephropathy. *Drug Saf* 2015; 38: 527–533

11. Wheeler DS, Giugliano RP, Rangaswami J. Anticoagulation-related nephropathy. *J Thromb Haemost* 2016; 14: 461–467

12. Brodsky SV. Anticoagulants and acute kidney injury: clinical and pathology. *Kidney Res Clin Pract* 2014; 33: 174–180

13. Ware K, Qamri Z, Ozcan A et al. N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy. *Am J Physiol Renal Physiol* 2013; 304: F1421–F1427

14. Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease. *J Am Soc Nephrol* 2007; 18: 414–420

15. Moreno JA, Martin-Cleary C, Gutierrez E et al. AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. *Clin J Am Soc Nephrol* 2012; 7: 175–184

16. Ware K, Brodsky P, Satoskar AA et al. Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. *J Am Soc Nephrol* 2011; 22: 1856–1862

17. Ryan M, Ware K, Qamri Z et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. *Nephrol Dial Transplant* 2013; 29: 2228–2234

18. August C, Atzeni A, Köster L et al. Acute renal failure in IgA nephropathy: aggravation by gross hematuria due to anticoagulant treatment. *J Nephrol* 2002; 15: 709–712

19. Abt AB, Carroll LE, Mohler JH. Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis. *Am J Kidney Dis* 2000; 35: 533–536

20. Yang J, Chen Y, Li X et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. *Int J Cardiol* 2013; 168: 4234–4243

21. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2013; 15: 625–651

22. Di Maso V, Carraro M, Bevilacqua E et al. Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile. *Clin Kidney J* 2014; 7: 605–608